Study Reports Link Between Alzheimer’s Cellular Abnormalities

Neurogenetics, Inc. has reported that a study published in the September issue of Neuron links a new mechanism-based therapeutic approach, licensed by the Company from Massachusetts General Hospital (MGH), to Alzheimer’s disease (AD). Researchers from the MGH Genetics and Aging Unit report that they have discovered a key link between two cellular abnormalities associated with the disease — mutations in genes encoding presenilin proteins and an altered handling of calcium inside cells.

While many cellular pathways can affect the flow of calcium into and out of a cell, the results from MGH tie one specific pathway, capacitative calcium entry (CCE), to the production of amyloid-beta42 (A-beta42). A-beta42 is a sticky protein fragment deposited in plaques found in the brains of people with AD. In normal cells, calcium is stored in a cellular compartment called the endoplasmic reticulum (ER), that is refilled through the CCE process.

The authors’ findings indicate that presenilin mutations known to be associated with the inherited form of early-onset AD inhibit the CCE process, resulting in increased production of A-beta42.

has exclusively licensed from MGH the approach of treating Alzheimer’s by modulating CCE. Kenneth A. Stauderman, Ph.D., Project Leader and Executive Director, Cell Biology and Physiology at Neurogenetics, commented,

“Based on these findings, has developed specific, cell-based assays to identify drugs that modulate the entry of calcium through the CCE pathway.

Targeting CCE for drug discovery represents a unique mechanistic approach for selectively inhibiting A-beta42 production.”

Neurogenetics, Inc., founded in April 2000, is a San Diego-based emerging biopharmaceutical company focused on the development of novel small molecule therapeutics for Alzheimer’s disease (AD).

Purchasing Dragon Pharmaceutical Ready for Use

Parabolan 100

Injectable Anabolic Steroid
Main Constituent: Trenbolone Hexahydrobenzylcarbonate
Manufacturer: Dragon Pharmaceutical
Unit: 1 X 10 ml (100 mg/ml)


Synthetic Anabolic Steroidal Agent
Basic Constituent: Oxandrolone
Branded by: Dragon Pharma LLC
Amount: 1 X 100 pills (50 mg/tab)

EQ 200 / Test E 200

Injectable Anabolic Steroid
Main Ingredient: Boldenone Undecylenate, Testosterone Enanthate
Produced by: Dragon Pharma LLC
Amount: 1 X 10 mL vial (400 mg/mL)

Enantat 250 - Cheap Price

Administration: Injection
Base Substance: Testosterone Enanthate
Producer: Dragon Pharma Labs
Pack: 20 x 10 mL vial (250 mg/mL)
Price: 20 x $30.00

Turanabol - Bulk Price

Administration: Oral
Base Constituent: Chlorodehydromethyltestosterone
Branded by: Dragon Pharmaceuticals
Pack: 10 x 100 pills (10 mg/pill)
Price: 10 x $70.00

Enantat 250 - Discount Price

Administration: Injection
Base Constituent: Testosterone Enanthate
Made by: Dragon Pharma LLC
Unit: 30 x 10 mL vial (250 mg/mL)
Price: 30 x $25.00

Primobolan 100 - Bulk Price

Administration: Injection
Main Constituent: Methenolone Enanthate
Made by: Dragon Pharma Labs
Package: 10 x 10 mL vial (100 mg/mL)
Price: 10 x $75.00

Clenbuterol - Bulk Price

Administration: Oral
Primary Constituent: Clenbuterol Hydrochloride
Producer: Dragon Pharma Labs
Amount: 10 x 100 tabs (40 mcg/pill)
Price: 10 x $25.00

Masteron 100 - Discount Price

Administration: Injection
Basal Constituent: Drostanolone Di-Propionate
Produced by: Dragon Pharma LLC
Amount: 30 x 10 mL vial (100 mg/mL)
Price: 30 x $35.00

Cypionat 250

Injectable Anabolic Steroid
Prime Chemical Name: Testosterone Cypionate
Branded by: Dragon Pharma Labs
Unit: 1 X 10 ml (250 mg/ml)

NPP 150

Injectable Steroid for Muscle Growth
Base Ingredient: Nandrolone Phenylpropionate
Produced by: Dragon Pharma
10 mL Sterile Multi-dose Vial (150 mg/mL)

Parabolan 100

Injectable Steroid for Muscle Growth
Basal Ingredient: Trenbolone Hexahydrobenzylcarbonate
Manufacturer: Dragon Pharma LLC
10 mL Sterile Multi-dose Vial (100 mg/mL)